Magnesium sulfate

Identification

Name
Magnesium sulfate
Accession Number
DB00653
Description

A small colorless crystal used as an anticonvulsant, a cathartic, and an electrolyte replenisher in the treatment of pre-eclampsia and eclampsia. It causes direct inhibition of action potentials in myometrial muscle cells. Excitation and contraction are uncoupled, which decreases the frequency and force of contractions. (From AMA Drug Evaluations Annual, 1992, p1083)

Type
Small Molecule
Groups
Approved, Investigational, Vet approved
Structure
Thumb
Weight
Average: 120.368
Monoisotopic: 119.936771076
Chemical Formula
MgO4S
Synonyms
  • Magnesium sulfate (1:1)
  • Magnesium sulfate anhydrous
  • Magnesium sulphate
  • magnesium(II) sulfate
  • Magnesiumsulfat
  • MgSO4

Pharmacology

Indication

Used for immediate control of life-threatening convulsions in the treatment of severe toxemias (pre-eclampsia and eclampsia) of pregnancy and in the treatment of acute nephritis in children. Also indicated for replacement therapy in magnesium deficiency, especially in acute hypomagnesemia accompanied by signs of tetany similar to those of hypocalcemia. Also used in uterine tetany as a myometriat relaxant.

Associated Conditions
Associated Therapies
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics

Magnesium sulfate is a small colorless crystal used as an anticonvulsant, a cathartic, and an electrolyte replenisher in the treatment of pre-eclampsia and eclampsia. It causes direct inhibition of action potentials in myometrial muscle cells. Excitation and contraction are uncoupled, which decreases the frequency and force of contractions. Magnesium sulfate is gaining popularity as an initial treatment in the management of various dysrhythmias, particularly torsades de pointes, and dyrhythmias secondary to TCA overdose or digitalis toxicity.

Mechanism of action

Magnesium is the second most plentiful cation of the intracellular fluids. It is essential for the activity of many enzyme systems and plays an important role with regard to neurochemical transmission and muscular excitability. Magnesium sulfate reduces striated muscle contractions and blocks peripheral neuromuscular transmission by reducing acetylcholine release at the myoneural junction. Additionally, Magnesium inhibits Ca2+ influx through dihydropyridine-sensitive, voltage-dependent channels. This accounts for much of its relaxant action on vascular smooth muscle.

TargetActionsOrganism
AVoltage-dependent L-type calcium channel
blocker
inactivator
Humans
Absorption
Not Available
Volume of distribution
Not Available
Protein binding

25-30%

Metabolism

None

Route of elimination

Magnesium is excreted solely by the kidney at a rate proportional to the serum concentration and glomerular filtration.

Half-life

43.2 hours (for newborns)

Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity

LD50 = 1200 mg/kg (rat, subcutaneous). May be harmful if swallowed. May act as an irritant. Adverse reactions include hypotension, ECG changes, diarrhea, urinary retention, CNS depression and respiratory depression.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcarboseThe risk or severity of hypoglycemia can be increased when Magnesium sulfate is combined with Acarbose.
AcebutololThe risk or severity of bradycardia can be increased when Magnesium sulfate is combined with Acebutolol.
AceclofenacThe risk or severity of hyperkalemia can be increased when Magnesium sulfate is combined with Aceclofenac.
AcemetacinThe risk or severity of hyperkalemia can be increased when Magnesium sulfate is combined with Acemetacin.
AcetazolamideThe therapeutic efficacy of Acetazolamide can be increased when used in combination with Magnesium sulfate.
AcetohexamideThe risk or severity of hypoglycemia can be increased when Magnesium sulfate is combined with Acetohexamide.
AcetophenazineThe therapeutic efficacy of Acetophenazine can be increased when used in combination with Magnesium sulfate.
AcetyldigitoxinMagnesium sulfate may increase the arrhythmogenic activities of Acetyldigitoxin.
Acetylsalicylic acidThe risk or severity of hyperkalemia can be increased when Magnesium sulfate is combined with Acetylsalicylic acid.
AclidiniumAclidinium may increase the central nervous system depressant (CNS depressant) activities of Magnesium sulfate.
Additional Data Available
  • Extended Description
    Extended Description
    Available for Purchase

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity
    Available for Purchase

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level
    Available for Purchase

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action
    Available for Purchase

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
No interactions found.

Products

Purchasing individual compounds or compound libraries for your research?
Learn More
Product Ingredients
IngredientUNIICASInChI Key
Magnesium sulfate heptahydrateSK47B8698T10034-99-8WRUGWIBCXHJTDG-UHFFFAOYSA-L
Magnesium sulfate monohydrateE2L2TK027P14168-73-1LFCFXZHKDRJMNS-UHFFFAOYSA-L
Active Moieties
NameKindUNIICASInChI Key
Magnesium cationionicT6V3LHY83822537-22-0JLVVSXFLKOJNIY-UHFFFAOYSA-N
ManganeseionicH6EP7W54577439-96-5WAEMQWOKJMHJLA-UHFFFAOYSA-N
MagnesiumunknownI38ZP9992A7439-95-4RSHAOIXHUHAZPM-UHFFFAOYSA-N
Sulfate ionionic7IS9N8KPMG14808-79-8QAOWNCQODCNURD-UHFFFAOYSA-L
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Magnesium SulfateInjection, solution500 mg/1mLIntramuscular; IntravenousAmerican Regent1990-09-302013-03-01US flag
Magnesium SulfateInjection, solution500 mg/1mLIntramuscular; IntravenousHF Acquisition Co LLC, DBA HealthFirst2019-12-11Not applicableUS flag
Magnesium SulfateInjection, solution500 mg/1mLIntramuscular; IntravenousCardinal Health2000-08-082016-10-31US flag
Magnesium SulfateInjection, solution500 mg/1mLIntramuscular; IntravenousMedical Purchasing Solutions, Llc2000-08-08Not applicableUS flag
Magnesium SulfateInjection, solution500 mg/1mLIntramuscular; IntravenousCardinal Health2000-08-082019-05-31US flag
Magnesium SulfateInjection, solution500 mg/1mLIntramuscular; IntravenousGeneral Injectables and Vaccines, Inc.2017-01-13Not applicableUS flag
Magnesium SulfateInjection, solution500 mg/1mLIntramuscular; IntravenousAmerican Regent1990-09-302012-08-01US flag
Magnesium SulfateInjection, solution40 mg/1mLIntravenousHF Acquisition Co LLC, DBA HealthFirst2018-12-21Not applicableUS flag
Magnesium SulfateInjection, solution500 mg/1mLIntramuscular; IntravenousHF Acquisition Co LLC, DBA HealthFirst2019-10-14Not applicableUS flag
Magnesium SulfateInjection, solution500 mg/1mLIntramuscular; IntravenousGeneral Injectables & Vaccines2010-08-012013-01-01US flag
Additional Data Available
  • Application Number
    Application Number
    Available for Purchase

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code
    Available for Purchase

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
50% Magnesium SulfateInjection, solution500 mg/1mLIntramuscular; IntravenousHf Acquisition Co. Llc, Dba Health First2018-08-25Not applicableUS flag
Magnesium SulfateInjection4 g/100mLIntravenousWG Critical Care, LLC2018-01-09Not applicableUS flag
Magnesium SulfateInjection, solution2 g/50mLIntravenousMylan Institutional LLC2020-10-02Not applicableUS flag
Magnesium SulfateInjection, solution500 mg/1mLIntramuscular; IntravenousHospira, Inc.2006-11-28Not applicableUS flag
Magnesium SulfateInjection, solution40 mg/1mLIntravenousFresenius Kabi Norge As2017-08-02Not applicableUS flag
Magnesium SulfateInjection, solution2 g/50mLIntravenousGland Pharma Limited2020-07-10Not applicableUS flag
Magnesium SulfateInjection1 g/100mLIntravenousWG Critical Care, LLC2016-03-08Not applicableUS flag
Magnesium SulfateInjection40 g/1000mLIntravenousWG Critical Care, LLC2018-01-09Not applicableUS flag
Magnesium SulfateInjection, solution500 mg/1mLIntramuscular; IntravenousX-GEN Pharmaceuticals, Inc.2014-02-232018-12-06US flag
Magnesium SulfateInjection, solution2 g/50mLIntravenousBaxter Healthcare Corporation2020-06-01Not applicableUS flag
Additional Data Available
  • Application Number
    Application Number
    Available for Purchase

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code
    Available for Purchase

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Assured Epsom SaltGranule100 g/100gOralHefei Yatai Daily Chemical Products Co., Ltd.2016-03-30Not applicableUS flag
Assured Epsom SaltGranule100 g/100gOralGreenbrier International, Inc.2016-06-14Not applicableUS flag
EpsalOintment400 mg/1gTopicalPress Chemical And Pharmaceutical Laboratories1957-01-15Not applicableUS flag
Epsom SaltGranule, for solution1 g/1gOral; TopicalPublix Super Markets, Inc2014-09-05Not applicableUS flag
Epsom SaltGranule, for solution1 g/1gOral; TopicalTARGET Corporation2019-01-15Not applicableUS flag
Epsom SaltGranule1.81 kg/100kgOral; TopicalKinray2012-06-142020-12-31US flag
Epsom SaltGranule1 g/1gOral; TopicalSam's West, Inc2019-02-28Not applicableUS flag
Epsom SaltGranule, for solution1 g/1gOral; TopicalMeijer Distribution, INC2013-04-26Not applicableUS flag
Epsom SaltGranule, for solution1 g/1gOral; TopicalDZA Brands, LLC2008-02-27Not applicableUS flag
Epsom SaltGranule, for solution1 g/1gOral; TopicalWalgreens2015-07-13Not applicableUS flag
Additional Data Available
  • Application Number
    Application Number
    Available for Purchase

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code
    Available for Purchase

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
Aqua De Folli Hair BoosterMagnesium sulfate (0.00024 g/100mL) + Sodium bicarbonate (0.006 g/100mL) + Zinc sulfate, unspecified form (0.0000022 g/100mL)LiquidTopicalROKIT HEALTHCARE Inc.2020-09-24Not applicableUS flag
Aqua De Folli Hair Booster MiniMagnesium sulfate (0.00024 g/100mL) + Sodium bicarbonate (0.006 g/100mL) + Zinc sulfate, unspecified form (0.0000022 g/100mL)LiquidTopicalROKIT HEALTHCARE Inc.2020-09-24Not applicableUS flag
Aqua De Folli Hair Booster ProMagnesium sulfate (0.00024 g/100mL) + Sodium bicarbonate (0.006 g/100mL) + Zinc sulfate, unspecified form (0.0000022 g/100mL)LiquidTopicalROKIT HEALTHCARE Inc.2020-09-24Not applicableUS flag
Calcium Lactate Et Magnesium SulfateMagnesium sulfate (65 mg) + Calcium lactate (260 mg)TabletOralBio Vita1987-12-312005-07-20Canada flag
ColPrep KitMagnesium sulfate (1.6 g/22.7g) + Potassium sulfate (3.13 g/22.7g) + Sodium sulfate decahydrate (17.5 g/22.7g)Powder, for solutionOralKVK-Tech, Inc.2016-12-272019-01-24US flag
Eau Purgative RigaMagnesium sulfate (2.4 g) + Sodium sulfate (1.056 g)LiquidOralGlendale Agencies1978-12-311996-11-29Canada flag
Elliotts BMagnesium sulfate (3 mg/10mL) + Calcium chloride dihydrate (2 mg/10mL) + D-glucose (8 mg/10mL) + Potassium chloride (3 mg/10mL) + Sodium bicarbonate (19 mg/10mL) + Sodium chloride (73 mg/10mL) + Sodium phosphate, monobasic (2 mg/10mL)InjectionIntrathecalLukare Medical, Llc2013-06-04Not applicableUS flag
Elliotts BMagnesium sulfate (3 mg/10mL) + Calcium chloride dihydrate (2 mg/10mL) + D-glucose (8 mg/10mL) + Potassium chloride (3 mg/10mL) + Sodium bicarbonate (19 mg/10mL) + Sodium chloride (73 mg/10mL) + Sodium phosphate, monobasic (2 mg/10mL)InjectionIntrathecalQOL Medical, LLC.2006-09-27Not applicableUS flag
Ellis TonicMagnesium sulfate (0.7 mg/15mL) + Cyanocobalamin (2 ug/15mL) + Dexpanthenol (3 mg/15mL) + Manganese sulfate (0.7 mg/15mL) + Nicotinamide (7 mg/15mL) + Pyridoxine hydrochloride (0.7 mg/15mL) + Riboflavin (0.6 mg/15mL) + Thiamine hydrochloride (0.5 mg/15mL) + Zinc sulfate, unspecified form (5 mg/15mL)LiquidOralBreckenridge Pharmaceutical, Inc.2001-01-012011-11-01US flag
Formule 1705 - LiqMagnesium sulfate (250 mg) + Ox bile extract (1.56 mg)LiquidOralBio Vita1993-12-312003-07-16Canada flag
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
Aqua De Folli Hair BoosterMagnesium sulfate (0.00024 g/100mL) + Sodium bicarbonate (0.006 g/100mL) + Zinc sulfate, unspecified form (0.0000022 g/100mL)LiquidTopicalROKIT HEALTHCARE Inc.2020-09-24Not applicableUS flag
Aqua De Folli Hair Booster MiniMagnesium sulfate (0.00024 g/100mL) + Sodium bicarbonate (0.006 g/100mL) + Zinc sulfate, unspecified form (0.0000022 g/100mL)LiquidTopicalROKIT HEALTHCARE Inc.2020-09-24Not applicableUS flag
Aqua De Folli Hair Booster ProMagnesium sulfate (0.00024 g/100mL) + Sodium bicarbonate (0.006 g/100mL) + Zinc sulfate, unspecified form (0.0000022 g/100mL)LiquidTopicalROKIT HEALTHCARE Inc.2020-09-24Not applicableUS flag
CentratexMagnesium sulfate (6.9 mg/1) + Cupric sulfate (0.8 mg/1) + Cyanocobalamin (15 ug/1) + Folic acid (1 mg/1) + Iron (106 mg/1) + Manganese sulfate (1.3 mg/1) + Nicotinamide (30 mg/1) + Calcium pantothenate (10 mg/1) + Pyridoxine hydrochloride (5 mg/1) + Riboflavin (6 mg/1) + Sodium ascorbate (200 mg/1) + Thiamine mononitrate (10 mg/1) + Zinc sulfate, unspecified form (18.2 mg/1)CapsuleOralCenturion Labs, LLC2009-06-14Not applicableUS flag
Concept DHAMagnesium sulfate (5 mg/1) + Ascorbic acid (25 mg/1) + Biotin (300 ug/1) + Cupric sulfate pentahydrate (2 mg/1) + Cyanocobalamin (12.5 ug/1) + Ferrous fumarate (53.5 mg/1) + Folic acid (1 mg/1) + Iron (38 mg/1) + Niacin (1.8 mg/1) + Omega-3-acid ethyl esters (200 mg/1) + Calcium pantothenate (5 mg/1) + Pyridoxine hydrochloride (25 mg/1) + Riboflavin (3 mg/1) + Thiamine mononitrate (2 mg/1) + Zinc sulfate, unspecified form (10 mg/1)Capsule, liquid filledOralUs Pharmaceutical Corporation2009-06-24Not applicableUS flag
Concept OBMagnesium sulfate (6.9 mg/1) + Ascorbic acid (210 mg/1) + Biotin (300 ug/1) + Cupric sulfate pentahydrate (800 ug/1) + Cyanocobalamin (10 ug/1) + Ferrous fumarate (130 mg/1) + Folic acid (1 mg/1) + Iron (92.4 mg/1) + Manganese sulfate (1.3 mg/1) + Niacin (20 mg/1) + Calcium pantothenate (7 mg/1) + Pyridoxine hydrochloride (25 mg/1) + Riboflavin (5 mg/1) + Thiamine mononitrate (5 mg/1) + Zinc sulfate, unspecified form (18.2 mg/1)CapsuleOralUs Pharmaceutical Corporation2009-01-01Not applicableUS flag
Ellis TonicMagnesium sulfate (0.7 mg/15mL) + Cyanocobalamin (2 ug/15mL) + Dexpanthenol (3 mg/15mL) + Manganese sulfate (0.7 mg/15mL) + Nicotinamide (7 mg/15mL) + Pyridoxine hydrochloride (0.7 mg/15mL) + Riboflavin (0.6 mg/15mL) + Thiamine hydrochloride (0.5 mg/15mL) + Zinc sulfate, unspecified form (5 mg/15mL)LiquidOralBreckenridge Pharmaceutical, Inc.2001-01-012011-11-01US flag
Magnesium SulfateMagnesium sulfate heptahydrate (500 mg/1mL)Injection, solutionIntramuscular; IntravenousAmerican Regent1990-09-302013-03-13US flag
Magnesium SulfateMagnesium sulfate heptahydrate (500 mg/1mL)Injection, solutionIntramuscular; IntravenousGeneral Injectables & Vaccines2010-09-012017-04-01US flag
Magnesium SulfateMagnesium sulfate (20 g/500mL)Injection, solutionIntravenousCantrell Drug Company2011-02-21Not applicableUS flag

Categories

ATC Codes
A06AD04 — Magnesium sulfateV04CC02 — Magnesium sulfateD11AX05 — Magnesium sulfateB05XA05 — Magnesium sulfateA12CC02 — Magnesium sulfate
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of inorganic compounds known as alkaline earth metal sulfates. These are inorganic compounds in which the largest oxoanion is sulfate, and in which the heaviest atom not in an oxoanion is an alkaline earth metal.
Kingdom
Inorganic compounds
Super Class
Mixed metal/non-metal compounds
Class
Alkaline earth metal oxoanionic compounds
Sub Class
Alkaline earth metal sulfates
Direct Parent
Alkaline earth metal sulfates
Alternative Parents
Inorganic salts / Inorganic oxides
Substituents
Alkaline earth metal sulfate / Inorganic oxide / Inorganic salt
Molecular Framework
Not Available
External Descriptors
magnesium salt, metal sulfate (CHEBI:32599)

Chemical Identifiers

UNII
ML30MJ2U7I
CAS number
7487-88-9
InChI Key
CSNNHWWHGAXBCP-UHFFFAOYSA-L
InChI
InChI=1S/Mg.H2O4S/c;1-5(2,3)4/h;(H2,1,2,3,4)/q+2;/p-2
IUPAC Name
magnesium(2+) ion sulfate
SMILES
[Mg++].[O-]S([O-])(=O)=O

References

Synthesis Reference

Shinichi Yamamoto, Akifumi Sekitani, "BASIC MAGNESIUM SULFATE GRANULE, AND PROCESS FOR PRODUCTION THEREOF." U.S. Patent US20110042297, issued February 24, 2011.

US20110042297
General References
  1. Blitz M, Blitz S, Hughes R, Diner B, Beasley R, Knopp J, Rowe BH: Aerosolized magnesium sulfate for acute asthma: a systematic review. Chest. 2005 Jul;128(1):337-44. [PubMed:16002955]
  2. Yokoyama K, Takahashi N, Yada Y, Koike Y, Kawamata R, Uehara R, Kono Y, Honma Y, Momoi MY: Prolonged maternal magnesium administration and bone metabolism in neonates. Early Hum Dev. 2010 Mar;86(3):187-91. doi: 10.1016/j.earlhumdev.2010.02.007. Epub 2010 Mar 12. [PubMed:20226604]
  3. Wedig KE, Kogan J, Schorry EK, Whitsett JA: Skeletal demineralization and fractures caused by fetal magnesium toxicity. J Perinatol. 2006 Jun;26(6):371-4. [PubMed:16724078]
  4. Nassar AH, Sakhel K, Maarouf H, Naassan GR, Usta IM: Adverse maternal and neonatal outcome of prolonged course of magnesium sulfate tocolysis. Acta Obstet Gynecol Scand. 2006;85(9):1099-103. [PubMed:16929415]
  5. Malaeb SN, Rassi AI, Haddad MC, Seoud MA, Yunis KA: Bone mineralization in newborns whose mothers received magnesium sulphate for tocolysis of premature labour. Pediatr Radiol. 2004 May;34(5):384-6. Epub 2004 Feb 18. [PubMed:14985884]
  6. Matsuda Y, Maeda Y, Ito M, Sakamoto H, Masaoka N, Takada M, Sato K: Effect of magnesium sulfate treatment on neonatal bone abnormalities. Gynecol Obstet Invest. 1997;44(2):82-8. [PubMed:9286718]
  7. Schanler RJ, Smith LG Jr, Burns PA: Effects of long-term maternal intravenous magnesium sulfate therapy on neonatal calcium metabolism and bone mineral content. Gynecol Obstet Invest. 1997;43(4):236-41. [PubMed:9194621]
  8. Santi MD, Henry GW, Douglas GL: Magnesium sulfate treatment of preterm labor as a cause of abnormal neonatal bone mineralization. J Pediatr Orthop. 1994 Mar-Apr;14(2):249-53. [PubMed:8188843]
  9. Holcomb WL Jr, Shackelford GD, Petrie RH: Magnesium tocolysis and neonatal bone abnormalities: a controlled study. Obstet Gynecol. 1991 Oct;78(4):611-4. [PubMed:1923163]
  10. Cumming WA, Thomas VJ: Hypermagnesemia: a cause of abnormal metaphyses in the neonate. AJR Am J Roentgenol. 1989 May;152(5):1071-2. [PubMed:2705341]
  11. Lamm CI, Norton KI, Murphy RJ, Wilkins IA, Rabinowitz JG: Congenital rickets associated with magnesium sulfate infusion for tocolysis. J Pediatr. 1988 Dec;113(6):1078-82. [PubMed:3193315]
  12. McGuinness GA, Weinstein MM, Cruikshank DP, Pitkin RM: Effects of magnesium sulfate treatment on perinatal calcium metabolism. II. Neonatal responses. Obstet Gynecol. 1980 Nov;56(5):595-600. [PubMed:7432730]
  13. Riaz M, Porat R, Brodsky NL, Hurt H: The effects of maternal magnesium sulfate treatment on newborns: a prospective controlled study. J Perinatol. 1998 Nov-Dec;18(6 Pt 1):449-54. [PubMed:9848759]
Human Metabolome Database
HMDB0014791
KEGG Drug
D01108
PubChem Compound
24083
PubChem Substance
46508411
ChemSpider
22515
RxNav
1311625
ChEBI
32599
ChEMBL
CHEMBL2021423
Therapeutic Targets Database
DAP000201
PharmGKB
PA450302
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Magnesium_sulfate
AHFS Codes
  • 56:12.00 — Cathartics and Laxatives
  • 28:12.92 — Miscellaneous Anticonvulsants
  • 40:12.00 — Replacement Preparations
MSDS
Download (72.1 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedNot AvailableNeuromuscular Block1
4CompletedPreventionAtrial Fibrillation (AF) / Coronary Artery Disease (CAD) / Surgery--Complications1
4CompletedPreventionCardiovascular Morbidity / Intubation Complications1
4CompletedPreventionHemorrhage1
4CompletedPreventionHyperalgesia1
4CompletedPreventionLiving Donor Liver Transplantation / Reperfusion Injury1
4CompletedPreventionNeoplasm, Gastric1
4CompletedPreventionPostoperative pain1
4CompletedPreventionPrevention of Postspinal Shivering1
4CompletedPreventionPsychomotor Agitation1

Pharmacoeconomics

Manufacturers
  • Abraxis pharmaceutical products
  • Hospira inc
Packagers
  • Denison Pharmaceuticals Inc.
  • Gallipot
  • Hospira Inc.
  • Pharmakon
  • Pharmedium
  • QOL Medical
  • Spectrum Pharmaceuticals
  • Vi-Jon Laboratories Inc.
  • Walgreen Co.
Dosage Forms
FormRouteStrength
PowderOral2.45 g
SolutionIntravenous1.79 g/L
Powder, for suspensionOral0.43 g
LiquidTopical
TabletOral
Powder, for solutionOral
Capsule, liquid filledOral
CapsuleOral
Injection, solutionParenteral200 mg
Injection, solutionParenteral4 g
Tablet, coatedOral5 mg
Injection, solution, concentrateIntramuscular; Intravenous493 mg/mL
Injection, solutionIntravenous3.38 g
InjectionIntrathecal
LiquidOral
OintmentTopical400 mg/1g
CrystalOral; Topical1 g/1g
GranuleOral1 g/1g
GranuleOral100 kg/100kg
GranuleOral; Topical1 g/1g
GranuleOral; Topical1.81 kg/100kg
Granule, for solutionOral; Topical1 g/1g
Granule, for solutionOral; Topical100 g/100g
Powder, for solutionOral
PowderTopical12 g/12g
GranuleTopical2.72 kg/2.72kg
GranuleOral; Topical100 g/100g
PowderOral
PowderOral100 %
PowderOral30 g/100g
EmulsionParenteral3.99 g/1085ml
EmulsionParenteral2.05 g/1085ml
Granule, for solutionOral1 g/1g
Powder, for solutionOral1000 mg/1g
Injection, solution, concentrateIntramuscular; Intravenous200 MG/ML
Injection, solution, concentrateIntramuscular; Intravenous400 MG/ML
Solution, concentrateOral17.51 g/176mL
SolutionOral3.276 g
Injection, emulsionIntravenous
Injection, emulsionIntravenous467 mg/100mL
InjectionIntravenous110 g
InjectionIntravenous165 g
InjectionIntravenous220 g
InjectionIntravenous275 g
InjectionIntravenous107 g
InjectionIntravenous143 g
InjectionIntravenous178 g
GranuleOral100 g/100g
SolutionOral600 mg/15mL
Injection, solution1 g/2mL
SolutionOral18.75 g/100mL
Injection, solutionParenteral493 mg/5mL
Injection, solutionParenteral985.9 mg/2mL
InjectionIntravenous1 g/100mL
InjectionIntravenous2 g/50mL
InjectionIntravenous20 g/500mL
InjectionIntravenous4 g/100mL
InjectionIntravenous4 g/50mL
InjectionIntravenous40 g/1000mL
Injection, solution1 g/10mL
Injection, solution10 g/20mL
Injection, solution4 g/20mL
Injection, solutionIntramuscular; Intravenous500 mg/1mL
Injection, solutionIntravenous2 g/50mL
Injection, solutionIntravenous20 g/500mL
Injection, solutionIntravenous20 g/250mL
Injection, solutionIntravenous4 g/100mL
Injection, solutionIntravenous4 g/50mL
Injection, solutionIntravenous40 mg/1mL
Injection, solutionIntravenous80 mg/1mL
Injection, solution5 g/10mL
SolutionOral50 mg/100mL
LiquidTopical
Injection, solutionIntravenous1 g/100mL
Injection, solutionIntravenous10 mg/1mL
Injection, solutionIntravenous2 g/100mL
LiquidIntramuscular; Intravenous
LiquidIntramuscular
SolutionIntramuscular; Intravenous
SolutionParenteral4929.5 mg/10mL
SolutionParenteral5000 mg/10mL
Injection, solutionParenteral100 mg/ml
SolutionIntramuscular; Intravenous15 %
SolutionIntramuscular; Intravenous1.2 mEq/ml
SolutionIntravenous1.5 g
InjectionIntravenous15 %
Tablet, coatedOral2.204 mg
Injection, solutionParenteral1 g/10ml
SolutionParenteral5 g/10ml
Granule, for solutionOral; Topical1 kg/1kg
LiquidIntravenous
PowderTopical10 g/10g
CrystalOral; Topical100 g/100g
CapsuleOral3000 IU
InjectionIntravenous200 MG/ML
InjectionIntravenous40 %
Powder, for solutionOral4 g
Tablet5 g
CapsuleOral2000 IU
For solutionTopical1 kg/1kg
CapsuleOral50 mcg
Injection, solutionIntravenous40 g/1000ml
GranuleOral3.63 kg/3.63kg
Granule, for solutionOral1 kg/1kg
SolutionOral50 g/100mL
CapsuleOral25 mg
EmulsionIntravenous
EmulsionParenteral1.6 g/l
EmulsionParenteral0.61 g/l
EmulsionParenteral440 mg
Injection, emulsionIntravenous4.4 g/1000ml
EmulsionParenteral3.1 g
Injection, emulsionIntravenous7.1 g/1000ml
EmulsionParenteral50 g
SolutionOral
EmulsionParenteral0.28 g
EmulsionParenteral0.18 g
KitOral
SolutionIntravenous2 g
Capsule, liquid filledOral1 mg
Solution, concentrateOral
LiquidOral1.77 g/5ml
IrrigantIrrigation
SolutionIrrigation
LiquidIrrigation
Injection, solutionIntravenous
InjectionIntravenous1500 mg/10ml
SolutionIntravenous
Powder, for solutionOral1.96 g
Capsule, liquid filledOral25 mg
Capsule, gelatin coatedOral
Capsule75 mg
Prices
Unit descriptionCostUnit
Elliotts b solution ampule4.71USD ml
Magnesium Sulfate 50% Solution 2ml Vial0.92USD vial
Magnesium sulfate powder0.29USD g
Magnesium-ns 6 g/50 ml bag0.29USD ml
Magnesium-ns 4 g/50 ml bag0.27USD ml
Magnesium-ns 3 g/50 ml bag0.26USD ml
Magnesium sulfate-ns 2 gm bag0.25USD ml
Magnesium sulfate-ns 1 gm bag0.24USD ml
Magnesium-d5w 1 gm/100 ml soln0.07USD ml
Magnesium-lr 20 g/500 ml0.03USD ml
Magnesium-lr 40 g/500 ml bag0.03USD ml
Magnesium-lr 50 g/500 ml bag0.02USD ml
Epsom salt 100% powder0.01USD g
Magnesium sulf 4% iv soln0.01USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)Region
US6946149No2005-09-202023-03-07US flag
Additional Data Available
  • Filed On
    Filed On
    Available for Purchase

    The date on which a patent was filed with the relevant government.

    Learn more

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)1124 °C (decomposition)Not Available
water solubility710 mg/mLNot Available
logP-0.91Not Available
Predicted Properties
PropertyValueSource
logP-0.84ChemAxon
pKa (Strongest Acidic)-3ChemAxon
Physiological Charge-2ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area80.26 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity11.53 m3·mol-1ChemAxon
Polarizability5.81 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption+0.7487
Blood Brain Barrier+0.9646
Caco-2 permeable-0.6267
P-glycoprotein substrateNon-substrate0.9137
P-glycoprotein inhibitor INon-inhibitor0.9194
P-glycoprotein inhibitor IINon-inhibitor0.9904
Renal organic cation transporterNon-inhibitor0.9521
CYP450 2C9 substrateNon-substrate0.8775
CYP450 2D6 substrateNon-substrate0.8213
CYP450 3A4 substrateNon-substrate0.7007
CYP450 1A2 substrateNon-inhibitor0.7767
CYP450 2C9 inhibitorNon-inhibitor0.7602
CYP450 2D6 inhibitorNon-inhibitor0.9115
CYP450 2C19 inhibitorNon-inhibitor0.7547
CYP450 3A4 inhibitorNon-inhibitor0.9759
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9577
Ames testNon AMES toxic0.5773
CarcinogenicityCarcinogens 0.8111
BiodegradationReady biodegradable0.943
Rat acute toxicity2.4160 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7988
hERG inhibition (predictor II)Non-inhibitor0.9446
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available

Targets

Kind
Protein group
Organism
Humans
Pharmacological action
Yes
Actions
Blocker
Inactivator
Curator comments
The magnesium regulates the channel gating by binding to the EF-hand motif region in the COOH-terminal tail of the α-subunit of the channel.
General Function
Voltage-gated calcium channel activity
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...

Components:
References
  1. Brunet S, Scheuer T, Klevit R, Catterall WA: Modulation of CaV1.2 channels by Mg2+ acting at an EF-hand motif in the COOH-terminal domain. J Gen Physiol. 2005 Oct;126(4):311-23. doi: 10.1085/jgp.200509333. Epub 2005 Sep 12. [PubMed:16157690]
  2. Bara M, Guiet-Bara A: Magnesium regulation of Ca2+ channels in smooth muscle and endothelial cells of human allantochorial placental vessels. Magnes Res. 2001 Mar;14(1-2):11-8. [PubMed:11300616]
  3. Kuo CC, Hess P: Block of the L-type Ca2+ channel pore by external and internal Mg2+ in rat phaeochromocytoma cells. J Physiol. 1993 Jul;466:683-706. [PubMed:8410712]
  4. Zhao M, Feng R, Shao D, Liu S, Lei M, Wang H, Sun X, Guo F, Hu H, Kameyama M, Hao L: Mg(2+)-dependent facilitation and inactivation of L-type Ca(2+) channels in guinea pig ventricular myocytes. J Pharmacol Sci. 2015 Nov;129(3):143-9. doi: 10.1016/j.jphs.2015.08.001. Epub 2015 Aug 7. [PubMed:26422671]

Drug created on June 13, 2005 07:24 / Updated on November 25, 2020 15:47

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates